Wei Wei1, Jiangyong Leng2, Hongxiang Shao2, Weidong Wang2. 1. Department of Urinary Surgery, Ningbo No.2 Hospital, Ningbo City, Zhejiang Province, China. Electronic address: zhangbingtg12@163.com. 2. Department of Urinary Surgery, Ningbo No.2 Hospital, Ningbo City, Zhejiang Province, China.
Abstract
BACKGROUND: Increasing evidence suggests that aberrant microRNAs expressions are significantly associated with cancer progression. Previous studies have reported that the relative expression of miR-1 is significantly downregulated in recurrent prostate cancer (PCa) samples when compared with nonrecurrent PCa tissues. However, whether miR-1 can serve as a novel predictive biomarker for PCa recurrence still remains unclear. MATERIALS AND METHODS: The patients with clinically localized PCa who underwent radical prostatectomy by the same medical team at the Department of Urology, Ningbo No.2 Hospital were enrolled in this study. We examined the miR-1 expression levels in recurrent and nonrecurrent tumor samples by quantitative reverse transcription polymerase chain reaction. Univariate and multivariate Cox proportional hazards analyses were used for the evaluation of potential predictors of PCa recurrence. RESULTS: During the study period, 78 patients (including 27 in the recurrent group and 51 in the nonrecurrent group) who were diagnosed with PCa and who underwent radical prostatectomy were included in the final analysis. MiR-1 was significantly downregulated in recurrent PCa tissues when compared with nonrecurrent tumor samples (P < 0.001). The univariate and multivariate Cox proportional hazards analyses indicated that miR-1 was the only independent prognostic factor for PCa recurrence (hazard ratio = 1.86; 95% CI: 1.21-2.94; P = 0.011). The area under the curve value of miR-1 for PCa recurrence was 0.885 (P < 0.001) with the sensitivity of 0.863 and specificity of 0.889 based on receiver operating characteristic curve analysis. CONCLUSIONS: This study identifies that miR-1 in PCa tissues can function as an important independent predictive factor for PCa recurrence.
BACKGROUND: Increasing evidence suggests that aberrant microRNAs expressions are significantly associated with cancer progression. Previous studies have reported that the relative expression of miR-1 is significantly downregulated in recurrent prostate cancer (PCa) samples when compared with nonrecurrent PCa tissues. However, whether miR-1 can serve as a novel predictive biomarker for PCa recurrence still remains unclear. MATERIALS AND METHODS: The patients with clinically localized PCa who underwent radical prostatectomy by the same medical team at the Department of Urology, Ningbo No.2 Hospital were enrolled in this study. We examined the miR-1 expression levels in recurrent and nonrecurrent tumor samples by quantitative reverse transcription polymerase chain reaction. Univariate and multivariate Cox proportional hazards analyses were used for the evaluation of potential predictors of PCa recurrence. RESULTS: During the study period, 78 patients (including 27 in the recurrent group and 51 in the nonrecurrent group) who were diagnosed with PCa and who underwent radical prostatectomy were included in the final analysis. MiR-1 was significantly downregulated in recurrent PCa tissues when compared with nonrecurrent tumor samples (P < 0.001). The univariate and multivariate Cox proportional hazards analyses indicated that miR-1 was the only independent prognostic factor for PCa recurrence (hazard ratio = 1.86; 95% CI: 1.21-2.94; P = 0.011). The area under the curve value of miR-1 for PCa recurrence was 0.885 (P < 0.001) with the sensitivity of 0.863 and specificity of 0.889 based on receiver operating characteristic curve analysis. CONCLUSIONS: This study identifies that miR-1 in PCa tissues can function as an important independent predictive factor for PCa recurrence.
Authors: Anson Ku; Jacob Fredsøe; Karina D Sørensen; Michael Borre; Mikael Evander; Thomas Laurell; Hans Lilja; Yvonne Ceder Journal: Front Oncol Date: 2021-03-25 Impact factor: 6.244
Authors: Ana Paula Alarcón-Zendejas; Anna Scavuzzo; Miguel A Jiménez-Ríos; Rosa M Álvarez-Gómez; Rogelio Montiel-Manríquez; Clementina Castro-Hernández; Miguel A Jiménez-Dávila; Delia Pérez-Montiel; Rodrigo González-Barrios; Francisco Jiménez-Trejo; Cristian Arriaga-Canon; Luis A Herrera Journal: Prostate Cancer Prostatic Dis Date: 2022-04-14 Impact factor: 5.455